keyword
MENU ▼
Read by QxMD icon Read
search

CRVO

keyword
https://www.readbyqxmd.com/read/29474305/use-of-the-ischemic-index-on-widefield-fluorescein-angiography-to-characterize-a-central-retinal-vein-occlusion-as-ischemic-or-nonischemic
#1
Akshay S Thomas, Mridul K Thomas, Avni P Finn, Sharon Fekrat
PURPOSE: To understand the relationship between baseline ischemic index (IsI) values on ultra-widefield fluorescein angiography and classification as ischemic central retinal vein occlusion (CRVO). METHODS: Single-center retrospective cohort study of CRVO patients imaged using ultra-widefield fluorescein angiography from which IsI values were calculated. An ischemic CRVO was defined as those eyes with an afferent pupillary defect and counting fingers acuity or worse or neovascularization during the first year of follow-up...
February 22, 2018: Retina
https://www.readbyqxmd.com/read/29447089/aflibercept-versus-bevacizumab-and-or-ranibizumab-for-recurrent-macular-edema-secondary-to-central-retinal-vein-occlusion
#2
Cem Ozgonul, Vaidehi S Dedania, Cagri G Besirli
PURPOSE: To compare functional and anatomic outcomes of treatment with intravitreal aflibercept versus bevacizumab and/or ranibizumab in patients with recurrent macular edema (ME) secondary to central retinal vein occlusion (CRVO). METHODS: Retrospective, comparative case series of patients with recurrent ME in the setting of CRVO. Patients with recurrent ME received treatment with aflibercept (Group 1, G1) or bevacizumab and/or ranibizumab (Group 2, G2). Primary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT)...
February 15, 2018: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29426292/pre-treatment-clinical-features-in-central-retinal-vein-occlusion-that-predict-visual-outcome-following-intravitreal-ranibizumab
#3
Kerr Brogan, Monica Precup, Amanda Rodger, David Young, David Francis Gilmour
BACKGROUND: Predicting how patients with central retinal vein occlusion (CRVO) will respond to intravitreal anti-VEGF is challenging. The purpose of this study was to identify pre-treatment clinical features in CRVO that predict visual acuity (VA) following intravitreal ranibizumab. METHODS: Medical records, fundus images and optical coherence tomography (OCT) scans of treatment naïve patients with CRVO receiving PRN intravitreal ranibizumab were retrospectively reviewed...
February 9, 2018: BMC Ophthalmology
https://www.readbyqxmd.com/read/29403585/effects-of-dexamethasone-implant-on-multifocal-electroretinography-in-central-retinal-vein-occlusion
#4
Muhammed Nurullah Bulut, Ümit Çallı, Güzide Akçay, Ulviye Kıvrak, Kezban Bulut, Yusuf Özertürk
Purpose: To investigate the effect of Ozurdex (dexamethasone intravitreal implant) on multifocal electroretinography (mfERG) findings during the treatment of macular edema secondary to the central retinal vein occlusion (CRVO). Methods: Fifteen eyes of 15 patients who were treated with Ozurdex implant due to CRVO-related macular edema were included in this study. Best corrected visual acuity (BCVA), central macular thickness (CMT), and mfERG evaluations were performed for all patients before injection of Ozurdex...
January 2018: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/29366614/correlation-between-ischemic-index-of-retinal-vein-occlusion-and-oxygen-saturation-in-retinal-vessels
#5
Irena Šínová, Jiří Řehák, Jana Nekolová, Naďa Jirasková, Petra Haluzová, Tereza Řeháková, Barbora Babková, Libor Hejsek, Martin Šín
PURPOSE: The aim of this study was to evaluate the relationship between the ischemic index and the oxygen saturation in retinal vessels in patients with retinal vein occlusion. DESIGN: Prospective, cross-sectional study. METHODS: We performed a prospective study. The cohort consisted of 43 eyes of 43patients with retinal vein occlusions (RVO), 23 of whom had central retinal vein occlusions (CRVO) and 20 who had branch retinal vein occlusions (BRVO)...
January 20, 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29364731/yc-1-inhibits-vegf-and-inflammatory-mediators-expression-on-experimental-central-retinal-vein-occlusion-in-rhesus-monkey
#6
Zhipeng Yan, Jianbin An, Qingli Shang, Nalei Zhou, Jingxue Ma
PURPOSES: To investigate the therapeutic potential of YC-1 for experimental central retinal vein occlusion (CRVO) of rhesus monkey. METHODS: Six adult rhesus monkeys were recruited in this study. Laser-induced CRVO was established in both eyes of all subjects. Intravitreal injection of YC-1 90 μl (200 μM with 0.01% dimethyl sulfoxide (DMSO) as vehicle) was administrated in right eye and 0.01% DMSO 90 μl in left eye respectively at 1 week after CRVO established...
January 24, 2018: Current Eye Research
https://www.readbyqxmd.com/read/29260119/one-year-outcomes-of-ziv-aflibercept-for-macular-edema-in-central-retinal-vein-occlusion
#7
Mohab Eldeeb, Errol W Chan, Chintan J Dedhia, Ahmad Mansour, Jay Chhablani
Purpose: To report the 12-month efficacy and safety outcomes of intravitreal ziv-aflibercept in macular edema secondary to central retinal vein occlusion (CRVO). Methods: Interventional case series documenting 12-month outcomes of intravitreal ziv-aflibercept (1.25 mg in 0.05 mL) in 6 patients with treatment-naive macular edema secondary to CRVO. All patients had comprehensive ophthalmic examination, spectral domain optical coherence tomography at baseline and all follow-up visits, and fluorescein...
December 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29225460/intravitreal-bevacizumab-injections-versus-dexamethasone-implant-for-treatment-na%C3%A3-ve-retinal-vein-occlusion-related-macular-edema
#8
Ilkka Laine, Juha-Matti Lindholm, Petteri Ylinen, Raimo Tuuminen
Purpose: To compare the short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO). Design: A retrospective single-center study. Subjects: A total of 135 eyes of 135 patients with BRVO (n=83) and CRVO (n=52). Methods: Changes in clinical parameters were recorded before treatment and at the first and third month after commencement of IVB (n=121) and DEX (n=14)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29222552/animal-models-of-retinal-vein-occlusion
#9
Meiaad Khayat, Noemi Lois, Michael Williams, Alan W Stitt
Purpose: To provide a comprehensive and current review on the available experimental animal models of retinal vein occlusion (RVO) and to identify their strengths and limitations with the purpose of helping researchers to plan preclinical studies on RVO. Methods: A systematic review of the literature on experimental animal models of RVO was undertaken. Medline, SCOPUS, and Web of Science databases were searched. Studies published between January 1, 1965, and March 31, 2017, and that met the inclusion criteria were reviewed...
December 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29185408/high-altitude-retinopathy-presenting-as-central-retinal-vein-occlusion-in-a-soldier
#10
Waseem Raja, Ahsan Mukhtar
A 33-year soldier, deployed at an altitude of 3,350 meters for two years, developed unilateral Central Retinal Vein Occlusion (CRVO) in the left eye. He had no risk factor for thrombosis and all thrombophilia screenings were negative. The patient was managed with intravitreal injections of anti-VEGF (Bevacizumab) every four weeks. He showed gradual improvement in the visual acuity over the next 3 months. Best corrected visual acuity (BCVA) after three months was 6/7.5; whereas, initially it was limited to hand movements only...
December 2017: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29185099/real-life-clinical-data-for-dexamethasone-and-ranibizumab-in-the-treatment-of-branch-or-central-retinal-vein-occlusion-over-a-period-of-six-months
#11
Sibylle Winterhalter, Annabelle Eckert, Gerrit-Alexander Vom Brocke, Alice Schneider, Dominika Pohlmann, Daniel Pilger, Antonia M Joussen, Matus Rehak, Ulrike Grittner
PURPOSE: To evaluate the therapeutic outcome for dexamethasone implant (DEX) or intravitreal ranibizumab (IVR) injections over 6 months in patients with macular edema due to branch or central retinal vein occlusion (BRVO, CRVO), in a real-life setting. METHODS: A total of 107 patients with BRVO or CRVO were included into this retrospective single-center observational study. Patients were treated with monotherapy consisting of DEX or three monthly IVR injections following a pro re nata regimen (PRN)...
November 28, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29133663/combined-central-retinal-artery-and-vein-occlusion-with-optic-perineuritis-following-herpes-zoster-dermatitis-in-an-immunocompetent-child
#12
Reema Bansal, Ramandeep Singh, Aastha Takkar, Vivek Lal
A 15-year-old healthy boy developed acute, rapidly progressing visual loss in left eye following herpes zoster dermatitis, with a combined central retinal artery occlusion (CRAO) and central retinal vein occlusion (CRVO), along with optic perineuritis. Laboratory tests were negative. Despite an empirical, intensive antiviral treatment with systemic corticosteroids, and vision could not be restored in the affected eye. Herpes zoster dermatitis, in an immunocompetent individual, may be associated with a combined CRAO and CRVO along with optic perineuritis, leading to profound visual loss...
November 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/29090058/central-retinal-vein-occlusion-like-appearance-a-precursor-stage-in-evolution-of-frosted-branch-angiitis
#13
Babulal Kumawat, Koushik Tripathy, Pradeep Venkatesh, Rohan Chawla, Yog Raj Sharma
PURPOSE: To report a young man with a central retinal vein occlusion (CRVO)-like appearance which later evolved to frosted branch angiitis (FBA). CASE REPORT: As 28-year-old Indian man presented with optic disc swelling, hyperemia, peripapillary hemorrhages, and dilated tortuous veins in the left eye, 6 months after being diagnosed with idiopathic FBA in the right eye. Within 3 days of presentation, the left eye developed FBA, which was promptly and successfully treated with oral steroids...
October 2017: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/29082677/predictive-value-of-baseline-biochemical-parameters-for-clinical-response-of-macular-edema-to-bevacizumab-in-eyes-with-central-retinal-vein-occlusion-a-retrospective-analysis
#14
V G Madanagopalan, Bibha Kumari
PURPOSE: To evaluate the influence of baseline biochemical parameters on the improvement in best corrected visual acuity (BCVA) and reduction in central foveal thickness (CFT) in patients treated with intravitreal bevacizumab (IVB; Avastin, Genentech, Inc) for macular edema (ME) secondary to central retinal vein occlusion (CRVO). DESIGN: A retrospective study. METHODS: Seventy eyes of 70 participants with CRVO who underwent IVB for ME and had at least 1 month of follow-up after the last injection were studied...
October 30, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/29074161/score2-report-5-vision-related-function-in-patients-with-macular-edema-secondary-to-central-retinal-or-hemiretinal-vein-occlusion
#15
RANDOMIZED CONTROLLED TRIAL
Ingrid U Scott, Maria J Figueroa, Neal L Oden, Michael S Ip, Barbara A Blodi, Paul C VanVeldhuisen
PURPOSE: To describe baseline vision-related function, measured with the National Eye Institute Visual Function Questionnaire (NEI VFQ-25), in patients with macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2); evaluate the baseline relationship between NEI VFQ-25 scores with visual acuity letter score (VALS) and central retinal thickness; and compare baseline NEI VFQ-25 scores in SCORE2 participants with those in normal-vision reference populations and patients in other retinal vein occlusion trials...
December 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29049410/metamorphopsia-associated-with-central-retinal-vein-occlusion
#16
Koichiro Manabe, Rie Osaka, Yuki Nakano, Yukari Takasago, Tomoyoshi Fujita, Chieko Shiragami, Kazuyuki Hirooka, Yuki Muraoka, Akitaka Tsujikawa
This prospective study aimed to investigate metamorphopsia in eyes with central retinal vein occlusion (CRVO) and included 28 eyes (28 patients) with unilateral CRVO that had macular edema (ME) in the acute phase. The ME was treated with anti-vascular endothelial growth factor agents. At baseline and at 1 and 6 months after initiation of treatment, quantitative measurements of metamorphopsia were performed using M-CHARTS and the retinal morphologic changes were examined by optical coherence tomography. At baseline, metamorphopsia was detected on M-CHARTS in 14 (50...
2017: PloS One
https://www.readbyqxmd.com/read/29020423/noninvasive-high-resolution-functional-macular-imaging-in-subjects-with-retinal-vein-occlusion
#17
Thalmon R Campagnoli, Gábor Márk Somfai, Jing Tian, Delia Cabrera DeBuc, William E Smiddy
BACKGROUND AND OBJECTIVES: Several imaging modalities have been developed to characterize ischemia inherent in retinal vascular diseases. This study aims to predict the impact and to better establish the mechanisms of visual deterioration. A high-resolution functional imaging device is used, yielding quantitative data for macular blood flow and capillary network features in healthy eyes and in eyes with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). PATIENTS AND METHODS: This prospective, cross-sectional, comparative case series measured blood flow velocities (BFVs) and noninvasive capillary perfusion maps (nCPMs) in macular vessels in patients with BRVO/CRVO and in healthy controls using the Retinal Function Imager (RFI; Optical Imaging, Rehovot, Israel)...
October 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29018760/management-of-macular-edema-due-to-central-retinal-vein-occlusion-the-role-of-aflibercept
#18
REVIEW
William Rhoades, Drew Dickson, Quan Dong Nguyen, Diana V Do
Central retinal vein occlusion (CRVO) can cause vision loss. The pathogenesis of CRVO involves a thrombus formation leading to increased retinal capillary pressure, increased vascular permeability, and possibly retinal neovascularization. Vision loss due to CRVO is commonly caused by macular edema. Multiple treatment modalities have been used to treat macular edema. Currently, the most common therapy used is intravitreal inhibition of vascular endothelial growth factor (VEGF). The three most widely used agents are aflibercept, bevacizumab, and ranibizumab and they are effective at blocking VEGF...
April 2017: Taiwan Journal of Ophthalmology
https://www.readbyqxmd.com/read/28979743/comparison-of-treatment-response-to-intravitreal-injection-of-triamcinolone-bevacizumab-and-combined-form-in-patients-with-central-retinal-vein-occlusion-a-randomized-clinical-trial
#19
Ghader Motarjemizadeh, Miaad Rajabzadeh, Naser Samadi Aidenloo, Rohollah Valizadeh
BACKGROUND: Central retinal vein occlusion (CRVO), is the second-most common disorder after diabetic retinopathy that threatens the vision related to retinal vessels. One of the main reasons of vision loss is CRVO in acute and chronic forms. OBJECTIVE: The aim of this study was to investigate the response to intravitreal injection of triamcinolone, bevacizumab, and a combined form in patients with CRVO. METHODS: This study was a double-blinded randomized clinical trial conducted on patients with CRVO who were referred to the ophthalmology clinic of Urmia Imam Khomeini Hospital from May 2015 to May 2016...
August 2017: Electronic Physician
https://www.readbyqxmd.com/read/28954021/alternative-ways-to-optimize-treatment-for-retinal-vein-occlusion-with-peripheral-capillary-non-perfusion-a-pilot-study
#20
Svetlana N Tultseva, Yury S Astakhov, Sergei A Novikov, Pavel A Nechiporenko, Alla B Lisochkina, Andranik Y Ovnanyan, Sergei Y Astakhov
Purpose: We compared the efficacy and safety of ranibizumab versus ranibizumab plus scatter laser photocoagulation (SLP) in patients with chronic post-central retinal vein occlusion (CRVO) macular edema (ME). Methods: This prospective non-randomized pilot study included 250 patients with peripheral retinal ischemia and CRVO-related ME. The mean follow-up period was 24.5 ± 6.5 months. The clinical assessments conducted included best corrected visual acuity, optical coherence tomography, and multi-field fluorescein angiography with measurement of the ischemic area...
July 2017: Arquivos Brasileiros de Oftalmologia
keyword
keyword
44183
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"